Tirzepatide for Metabolic Dysfunction– Associated Steatohepatitis with Liver Fibrosis por Walter Suárez Carmona | Feb 3, 2025
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis por Walter Suárez Carmona | Feb 3, 2025
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary por Walter Suárez Carmona | Feb 3, 2025
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity por Walter Suárez Carmona | Feb 3, 2025
